Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274307 | 0.96 | CCR2 (0.46) | CCR2KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3274756 | 0.93 | CCR2 (0.46) | CCR2KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3274081 | 0.91 | CCR2 (0.55) | CCR2KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3275522 | 0.90 | CCR2 (0.56) | CCR2KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL15103932 | 0.90 | CCR2 (0.46) | CCR2KCNH2PTGDRPTGDR2CCR1 | |
| SCHEMBL3275572 | 0.90 | CCR2 (0.54) | CCR2KCNH2GAAPTGDRPTGDR2 | |
| SCHEMBL15103871 | 0.90 | ALDH1A1 (0.51) | CCR2KCNH2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3149931 | 0.89 | CCR2 (0.44) | CCR2SMN1; SMN2ALDH1A1GAACCR1 | |
| SCHEMBL3273918 | 0.89 | CCR2 (0.55) | CCR2KCNH2PTGDRPTGDR2 | |
| SCHEMBL15103750 | 0.89 | CCR2 (0.46) | CCR2KCNH2PTGDRPTGDR2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | claimed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | claimed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | claimed |
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | CCR2 380/4885KCNH2 55/4885SMN1; SMN2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.